Introduction
Angiotensin II receptor blockers are the latest generation of anti-hypertensive drugs. Losartan, an angiotensin II receptor blocker, has been reported to have protective effects against hypertensive organ damage as well as on systemic blood pressure. The LIFE study (1) was a prospective, double-blinded and randomized clinical trial in which losartan was shown to be more effective at preventing cardiovascular morbidity and death than atenolol. In the LIFE study, interest was focused on the preventive effects of losartan on primary fatal or nonfatal strokes. Losartan appeared to have beneficial effects on cerebral vessels beyond a reduction in blood pressure.
The effect of angiotensin II receptor blockers on cerebral hemodynamics is still controversial. Previous studies have suggested that angiotensin II receptor blockers do not influence cerebral blood flow under baseline conditions. Vraamark et al. (2) reported that candesartan shifted the autoregulation curve towards the left in hypertensive rats. Ström-berg et al. (3) reported that losartan shifted the upper limit of the autoregulation curve towards the right in rats with experimental hypertension induced by angiotensin II. Finally, in an experiment by Näveri et al. (4) , losartan increased cerebrovascular resistance in rats with acute hypotension induced by hemorrhage.
However, these previous results were based on animal models and some observed acute effects of angiotensin II receptor blockers on cerebral blood flow. Few reports have evaluated the chronic effects of losartan on cerebral hemodynamics in hypertensive patients. The purpose of this paper was to elucidate the hemodynamic status before and after losartan administration using positron emission tomography and an acetazolamide challenge.
Methods

Subjects
Subjects were selected from patients with essential hypertension, defined according to the criteria of the VIth Joint National Committee (5). We excluded patients who met any of the following conditions: age under 40 years; severe hypertension (systolic blood pressure > 200 mmHg or diastolic blood pressure > 120 mmHg) or uncontrolled diabetes (HbA1c > 8%); a history of stroke within the previous 3 months; angina pectoris or myocardial infarction; heart failure; renal failure (serum creatinine > 2 mg/dl); severe stenosis (> 50%) of the carotid artery and/or middle cerebral artery (assessed by ultrasonography and magnetic resonance angiography); currently taking anti-hypertensive drugs; atherosclerosis obliterans; any type of dementia; or currently taking tranquilizers, histamine blockers, analgesics, or diuretics.
Eighteen patients were nominated for the study. Of these 18 patients, 10 patients agreed to participate in the study and provided their written informed consent after receiving a detailed explanation of the study, including the irradiation dosage used in the positron emission tomography procedure. The profiles of these patients are shown in Table 1 . The mean age of the patients was 60.8±3.4 (mean±SD) years. Of the 10 patients, one had a non-disabling pure motor hemiparesis due to lacunar infarction and four had mild asymptomatic white matter ischemic lesions (Fazekas (6) grade 1, minimal patchy white matter foci), as revealed by brain magnetic resonance imaging. Three patients had hypercholesterolemia, and none had diabetes. All portions of the study were performed in agreement with the ethical guidelines of the hospital.
Drug Control
On enrollment in the study, the clinical history of the patients was thoroughly checked. The administration of drugs that might influence the baseline cerebral blood flow was prohibited during the study period. Prescriptions for chronic diseases such as hypercholesterolemia were continued unchanged throughout the study period. Patients underwent an initial cerebral blood flow measurement using positron emission tomography with [O-15] labeled water. Subsequently, the patients received a daily oral dose of losartan (NU-LOTAN; Banyu Pharmaceutical Co., Ltd., Tokyo, Japan) titrated to 50 mg. Follow-up examinations were performed every 2 to 4 weeks, and the drug dosage was increased up to 100 mg a day unless the patient reached a target sitting blood pressure of less than 140/90 mmHg. When the sitting blood pressure reached the target range and stabilized with losartan administration, the patient underwent a second cerebral blood flow measurement. 
Cerebral Blood Flow Measurement
All patients underwent two cerebral blood flow measurements. As described above, the first and second measurements were performed before and after the administration of losartan, respectively. We used a high-performance positron emission tomography scanner (SET-2400W; Shimadzu Co., Kyoto, Japan) that uses 63 slices (slice thickness of 3.1 mm) and a spatial resolution of 3.7 mm full width at half maximum. Regional cerebral blood flow was quantitatively measured using positron emission tomography, an [O-15] labeled water injection, and an autoradiographic method (7). During each session, the patient was asked to lie on the scanner bed in a supine position in a quiet, dimly lit room. One session consisted of four scans. First, two consecutive scans were performed for the baseline condition. Then, after the intravenous administration of acetazolamide titrated to 1,000 mg, two additional scans were performed at an interval of 10 min. At the end of every scan, the patient's blood pressure, pulse rate, and arterial blood gas tension were measured. The data obtained for the baseline condition were averaged using the two measurements.
Blood Pressure Measurements
Blood pressure was measured using a mercury sphygmomanometer and a 6-inch cuff, with the patient lying supine on the scanner bed. Systolic and diastolic blood pressure (Korotkoff phase I and phase V, respectively) were averaged using two readings obtained 3 min apart.
Cerebral Blood Flow Image Analysis
The regional cerebral blood flow image data set obtained by the positron emission tomography scanner was transformed stereotaxically into an identical normal brain template using statistical parametric mapping-99 software (8) (SPM99; Wellcome Department of Cognitive Neurology, University College London, London, UK) running in a MATLAB (The MathWorks Inc., Natic, USA) environment. Identical regions of interest (the whole cerebrum, whole cerebellum, bilateral upper and lower frontal lobes, bilateral temporal lobes, bilateral occipital lobes, bilateral parietal lobes, bilateral basal ganglia areas, and bilateral thalami) were drawn on standardized cerebral blood flow images. Except for the whole cerebrum and whole cerebellum, the regions of interest were drawn on the gray matter of each region and consisted of multiple small circular regions of interest (20 mm in diameter) linked together.
Statistical Analysis
Blood pressure, pulse rate, arterial blood gas tensions, and baseline cerebral blood flow measurements obtained before and after treatment were compared using paired t-tests. The effects of acetazolamide on systemic conditions and an increased cerebral blood flow were analyzed using a one-way repeated-measure analysis of variance (ANOVA) followed by Bonferroni's multiple comparison. These analyses were performed using statistical analysis software (SPSS 11.5J; SPSS Japan Inc., Tokyo, Japan) on a personal computer running Windows. Differences were considered to be significant when the statistical p value was less than 0.05.
Results
Losartan was well tolerated by all the patients and no complications or adverse effects occurred. The period of losartan therapy ranged from 8 to 23 weeks, and the final losartan dosages required to control the patients' blood pressures were 50 mg/day in 5 patients and 100 mg/day in 5 (Table 1) . Of the 10 patients in the study, 8 patients safely underwent two acetazolamide challenges; the examination was well tolerated in these patients. Two patients (Nos. 2 and 4 in Table 1 ) refused to undergo the acetazolamide challenge. Thus, the physiological parameters and baseline regional cerebral blood flow were assessed in 10 patients, while the changes in these parameters after an acetazolamide challenge were assessed in SBP and DBP, systolic and diastolic blood pressure, respectively; PaCO2 and PaO2, arterial gas tension for carbon dioxide and oxygen, respectively; ACZ10 and ACZ20, 10 and 20 min after acetazolamide injection, respectively; bpm, beats per minute. Data are listed in mean±SD. *p<0.01 vs. baseline in before losartan. Table 2 shows the physiological data for the patients. The baseline systemic blood pressures before and after losartan administration were 153.8 ±10.8 / 96.0 ±6.5 (systolic mean ±SD/ diastolic mean ±SD) mmHg and 133.4 ±11.2 / 83.6 ±6.5 mmHg, respectively. Both the systolic and diastolic blood pressures decreased significantly after losartan administration. Arterial blood gas tensions, arterial pH, and the pulse rate measured before and after losartan administration did not change significantly. Although a slight elevation in blood pressure was observed during the acetazolamide challenges, both before and after losartan administration, the effect of the acetazolamide challenge on the baseline blood pressure values was not significant.
None of the regional cerebral blood flow images obtained during the positron emission tomography examinations showed major abnormalities, and all of the images were successfully transformed into standardized normal brain images using the SPM99 software.
As the peak response time (i.e., 10 or 20 min after acetazolamide injection) to acetazolamide differed by patient, we selected individual maximum cerebral blood flow value for the analysis. Table 3 shows the individual changes in global cerebral blood flow, the maximum percent increase in cerebral blood flow (INC%max) induced by acetazolamide, mean systemic blood pressure, and arterial partial pressure of carbon dioxide. In 3 patients (Nos. 5, 8, and 9), there was a considerable decrease in global cerebral blood flow after losartan administration. In contrast, the other 2 patients (Nos. 6 and 10), showed considerable increases in global cerebral blood flow after losartan administration. Table 4 shows the mean global and regional baseline cerebral blood flow values and the INC%max for the two conditions. The mean baseline global cerebral blood flow values obtained before and after losartan administration were 38.4 ±6.9 ml/min/100 g and 38.2±8.2 ml/min/100 g, respectively; these values were not significantly different. The mean global INC%max before and after losartan administration were 42.4 ±17.0% and 43.0±8.9%, respectively. No significant differences among the mean global INC%max values were observed. The same relationships were seen for every brain region examined, i.e., there were no significant differences in the baseline cerebral blood flow and INC%max values obtained before and after losartan administration.
Discussion
In the present study, losartan was shown to reduce blood pressure without deteriorating baseline cerebral blood flow or the cerebral blood flow response to acetazolamide in patients with essential hypertension. No regional differences in this effect were observed in the brain. Only a few previous studies have evaluated the effect of losartan on the brain in hypertensive patients. Matulla et al. (9) indirectly suggested that losartan did not change the resting global cerebral blood flow in normal individuals, based on ultrasonography findings. This previous study measured blood flow velocities in the middle cerebral artery, not the cerebral blood flow, and only evaluated the acute effects of losartan. The present clinical study evaluated the chronic effects of losartan on regional cerebral blood flow. In this study, three patients (Nos. 5, 8, and 9) out of 10 showed considerable decrease in baseline cerebral blood flow after losartan administration. In one patient (No. 5), the decrease might be explained by the change in arterial carbon dioxide gas tension. In the rest 2, although it was possible that losartan affected the baseline cerebral blood flow, it was also possible that the drift in cerebral blood flow measurement by positron emission tomography partially influenced the result. The reproducibility of the method has been reported to have a SD of almost 10% (10) .
Positron emission tomography, [O-15] labeled water, and SPM99 software were used in this study. These methods offer gCBF, global cerebral blood flow; INC%max, maximum percent increase of gCBF from baseline after acetazolamide injection; BP, systemic blood pressure; PCO2, arterial partial pressure of carbon dioxide; PtNo, patient number.
some advantages for this type of study. Regional cerebral blood flow measurement using positron emission tomography and [O-15] labeled water is a reliable and quantitative method. A single measurement requires only 2 min to perform, and measurements can be repeated every 10 min because the half-life of [O-15] is as short as 2 min. This characteristic enabled us to measure both the baseline cerebral blood flow and the cerebral blood flow after an acetazolamide challenge within about 1 h. To quantify the regional cerebral blood flow, we used a region of interest-based analysis. This type of analysis using native cerebral blood flow images is limited by positional changes of the head from session-to-session and by inter-subject differences in the shape of the brain. SPM99 have been developed as an analysis tool for detecting areas with statistically significant signal changes among images obtained under different scanning conditions and for different individuals. Using the SPM99 module enabled us to correct for inter-scan head motion and to minimize inter-individual structural differences in the head. Using these techniques, corresponding regions of interest were obtained in all of the patients. Theoretically, organ blood flow is determined by blood pressure and vascular resistance. Our data indicated that losartan reduced the cerebral vascular resistance whereas the blood pressure reduced. Unlike in the present study, Näveri et al. (4) reported that the administration of losartan in a hemorrhagic hypotensive animal model increased cerebrovascular resistance. These conflicting results may be explained by the fact that Näveri et al. examined the acute effects of losartan in an experimental animal model, whereas our data were focused on the chronic effects of losartan in humans in a clinical environment.
Under physiological conditions, global cerebral blood flow is controlled by autoregulation, irrespective of changes in systemic blood pressure. The vascular responses of large arteries and the resistance of small cerebral vessels play pivotal roles in this mechanism. Furthermore, the renin-angiotensin system is known to have a large effect on the regulation of vascular tonus (2) (3) (4) 11) . It is thus of concern that losartan administration may have shifted the cerebral autoregulation curve to the left or right. However, elucidating the upper and lower limits of the cerebral autoregulation curve is difficult in real patients. In the present study, patients were categorized as having mild or moderate hypertension, and thus the average right shift of the autoregulation curve was likely to be small. It remains unclear whether or not losartan affects the cerebral hemodynamics in patients with severely impaired autoregulation.
Instead of elucidating the autoregulation range, we applied an acetazolamide challenge to test cerebral vasomotor reactivity. The intravenous administration of acetazolamide titrated to 1,000 mg causes a dramatic dilatation in the cerebral resistant vessels as a result of extracellular acidosis (12) , which in turn causes the regional cerebral blood flow to increase to its maximum possible value. This effect has been used to evaluate cerebral vasomotor reactivity and the cerebral perfusion reserve (13) . The cerebral perfusion reserve is considered a safety margin against a drift in cerebral perfusion pressure. This idea has been supported by several previous studies (14−16) which concluded that compromised Table 4 . Regional Cerebral Blood Flow at Baseline and Cerebral Perfusion Reserve cerebral perfusion reserve was associated with an increased risk of cerebral ischemic events. Our data suggested that losartan did not affect the cerebral perfusion reserve. This property is thought to be beneficial to patients with cerebral ischemic lesions, such as those seen in the present study.
Stroke prevention is a major goal in the treatment of hypertension. Inada et al. (17) reported that candesartan treatment reduced the incidence of stroke in stroke-prone spontaneously hypertensive rats. In the LIFE (1) losartan was more effective at preventing fatal and non-fatal stroke events than atenorol (adjusted risk reduction, 24.9%) and resulted in fewer adverse events. The results raise the question of whether angiotensin II receptor blockers are superior to angiotensin-converting enzyme inhibitors. In patients with symptomatic heart failure (18) or acute myocardial infarction (19) , losartan was equally beneficial but not superior to captopril. Which of these drugs is superior for stroke management remains uncertain, but both drugs owe their protective effects to the inhibition of the renin-angiotensin system. Many experimental studies have proved that the inhibition of the renin-angiotensin system modulates vascular tonus (2−4, 10), prevents (20) or improves (21, 22) vascular wall remodeling or improves endothelial functions (23, 24) . In a human study, candesartan reduced oxidative stress and inflammation (25) , which were related to organ damage. Angiotensin II receptor blockers as well as angiotensin converting enzyme inhibitors seem to be promising for the prevention of stroke.
In conclusion, losartan has been accepted as an effective anti-hypertensive drug with good tolerability. Our results showed that losartan effectively lowered the blood pressure without affecting the baseline cerebral blood flow or cerebral perfusion reserve in patients with mild to moderate hypertension. This characteristic protects the brain from unexpected episodes of hypotension during treatment with losartan. The effect of this drug on the brain in patients with stroke or in those with severe hypertension awaits further study.
